Identification and characterization of angiogenesis targets through proteomic profiling of endothelial cells in human cancer tissues

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Mesri, Mehdi ^a   Birse, Charlie ^a   Heidbrink, Jenny ^b   McKinnon, Kathy ^c   Brand, Erin ^b   Bermingham, Candy Lee ^d   Feild, Brian ^e   FitzHugh, William ^f   He, Tao ^g   Ruben, Steve ^h   Moore, Paul A ⁱ  

^a CELERA   (United States)

^b MEDIMMUNE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d ANGION BIOMEDICA CORP   (United States)

^e Shimadzu Scientific Instruments   (United States)

^f 5AM Solutions ^*  (United States)

^g PFIZER INC   (United States)

^h SRM Bio Consulting   (United States)

ⁱ Analytical Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS, CD146; B7 ANTIGENS; COLONIC NEOPLASMS; ENDOTHELIUM, VASCULAR; GENE KNOCKDOWN TECHNIQUES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEOME; RNA, SMALL INTERFERING; SODIUM-POTASSIUM-EXCHANGING ATPASE; TANDEM MASS SPECTROMETRY; TUMOR CELLS, CULTURED;

EID: 84893543900     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078885     Document Type: Article

References (34)

1. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438: 967-974. (Pubitemid 43093963)
2. Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-739. (Pubitemid 37328908)
3. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358: 2039-2049.
4. Neri D, Bicknell R (2005) Tumour vascular targeting. Nat Rev Cancer 5: 436-446. (Pubitemid 40791486)
5. Ahlskog J, Paganelli G, Neri D (2006) Vascular tumor targeting. Q J Nucl Med Mol Imaging 50: 296-309. (Pubitemid 46157611)
6. Semenza GL (2008) A new weapon for attacking tumor blood vessels. N Engl J Med 358: 2066-2067.
7. Clarke MS, West DC (1991) The identification of proliferation and tumour-induced proteins in human endothelial cells: a possible target for tumour therapy. Electrophoresis 12: 500-508.
8. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, et al. (2000) Genes expressed in human tumor endothelium. Science 289: 1197-1202. (Pubitemid 30650733)
9. Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, et al. (2007) Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 11: 539-554. (Pubitemid 46856908)
10. Huminiecki L, Bicknell R (2000) In silico cloning of novel endothelial-specific genes. Genome Res 10: 1796-1806.
11. Pasqualini R, Ruoslahti E (1996) Organ targeting in vivo using phage display peptide libraries. Nature 380: 364-366. (Pubitemid 26097120)
12. Arap W, Pasqualini R, Ruoslahti E (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377-380. (Pubitemid 28063372)
13. Castronovo V, Waltregny D, Kischel P, Roesli C, Elia G, et al. (2006) A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer. Mol Cell Proteomics 5: 2083-2091. (Pubitemid 44817020)
14. Rybak JN, Ettorre A, Kaissling B, Giavazzi R, Neri D, et al. (2005) In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat Methods 2: 291-298. (Pubitemid 41131011)
15. Bobbitt JM (1956) Periodate oxidation of carbohydrates. Adv Carbohydr Chem 48: 1-41.
16. Zhang H, Li XJ, Martin DB, Aebersold R (2003) Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol 21: 660-666. (Pubitemid 36638093)
17. Tuzmen S, Kiefer J, Mousses S (2007) Validation of short interfering RNA knockdowns by quantitative real-time PCR. Methods Mol Biol 353: 177-203. (Pubitemid 350183278)
18. Sasaki K, Kiuchi Y, Sato Y, Yamamori S (1991) Morphological analysis of neovascularization at early stages of rat splenic autografts in comparison with tumor angiogenesis. Cell Tissue Res 265: 503-510.
19. Solovey A, Lin Y, Browne P, Choong S, Wayner E, et al. (1997) Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 337: 1584-1590. (Pubitemid 27509761)
20. Ohga N, Ishikawa S, Maishi N, Akiyama K, Hida Y, et al. (2012) Heterogeneity of Tumor Endothelial Cells Comparison between Tumor Endothelial Cells Isolated from High- and Low-Metastatic Tumors. Am J Pathol.
21. Langenkamp E, Molema G (2009) Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer. Cell Tissue Res 335: 205-222.
22. Jouve N, Despoix N, Espeli M, Gauthier L, Cypowyj S, et al. (2013) The involvement of CD146 and its novel ligand Galectin-1 in apoptotic regulation of endothelial cells. J Biol Chem 288: 2571-2579.
23. Ouhtit A, Gaur RL, Abd Elmageed ZY, Fernando A, Thouta R, et al. (2009) Towards understanding the mode of action of the multifaceted cell adhesion receptor CD146. Biochim Biophys Acta 1795: 130-136.
24. Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, et al. (2001) B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2: 269-274. (Pubitemid 33706005)
25. Loo D, Alderson RF, Chen FZ, Huang L, Zhang W, et al. (2012) Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res 18: 3834-3845.
26. Zang X, Sullivan PS, Soslow RA, Waitz R, Reuter VE, et al. (2010) Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol 23: 1104-1112.
27. Wandel E, Saalbach A, Sittig D, Gebhardt C, Aust G (2012) Thy-1 (CD90) Is an Interacting Partner for CD97 on Activated Endothelial Cells. J Immunol 188: 1442-1450.
28. Saalbach A, Hildebrandt G, Haustein UF, Anderegg U (2002) The Thy-1/Thy-1 ligand interaction is involved in binding of melanoma cells to activated Thy-1-positive microvascular endothelial cells. Microvasc Res 64: 86-93. (Pubitemid 34713234)
29. He J, Liu Y, Zhu T, Zhu J, Dimeco F, et al. (2011) CD90 is identified as a marker for cancer stem cells in primary high-grade gliomas using tissue microarrays. Mol Cell Proteomics.
30. Wetzel A, Chavakis T, Preissner KT, Sticherling M, Haustein UF, et al. (2004) Human Thy-1 (CD90) on activated endothelial cells is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Immunol 172: 3850-3859. (Pubitemid 38337972)
31. Jurisic G, Iolyeva M, Proulx ST, Halin C, Detmar M (2010) Thymus cell antigen 1 (Thy1, CD90) is expressed by lymphatic vessels and mediates cell adhesion to lymphatic endothelium. Exp Cell Res 316: 2982-2992.
32. Lee WS, Jain MK, Arkonac BM, Zhang D, Shaw SY, et al. (1998) Thy-1, a novel marker for angiogenesis upregulated by inflammatory cytokines. Circ Res 82: 845-851. (Pubitemid 28234575)
33. Yoshimura SH, Iwasaka S, Schwarz W, Takeyasu K (2008) Fast degradation of the auxiliary subunit of Na+/K+-ATPase in the plasma membrane of HeLa cells. J Cell Sci 121: 2159-2168.
34. Anderson NL, Anderson NG (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1: 845-867.